Q32 news

Latest 3 stories · newest Jul 15, 2026

Q32

Q32 Bio enters underwriting agreement for common stock sale.

Q32 Bio Inc. agreed to sell shares and pre-funded warrants to underwriters including Morgan Stanley. The proposed transaction aims to raise capital under an existing S-3 registration statement.

Offering Jul 15, 2026 sentiment 0.00 SEC filing ↗

Q32

Q32 Bio Reports Topline Results for SIGNAL-AA Part B

Q32 Bio Inc. released 36-week topline results for the Part B of its Phase 2a SIGNAL-AA clinical trial. These data are critical for assessing the efficacy and safety profile of bempikibart in treating alopecia areata.

Earnings Jul 13, 2026 sentiment 0.00 SEC filing ↗

Q32

Q32 Bio issues pre-funded warrants to purchase common stock

Q32 Bio Inc. filed an 8-K exhibiting pre-funded warrant terms dated May 26, 2026, allowing holders to purchase common shares at specified exercise prices. The offering expands the company's capital raising toolkit through derivative securities.

Offering May 27, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same Q32 feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/Q32/newsSTART FREE